Predictors of 1-year visual outcome in neovascular age-related macular degeneration following intravitreal ranibizumab treatment
Author:
Publisher
Wiley
Subject
Ophthalmology,General Medicine
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1755-3768.2011.02268.x/fullpdf
Reference22 articles.
1. Effectiveness of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration in a Canadian retina practice: a retrospective review;Bandukwala;Can J Ophthalmol,2010
2. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration;Boyer;Ophthalmol,2007
3. A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration;Boyer;Ophthalmol,2010
4. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition’s impact on vision outcomes-TAP report no.3;Bressler;Arch Ophthalmol,2002
5. Ranibizumab versus verteporfin for neovascular age-related macular degeneration;Brown;N Engl J Med,2006
Cited by 50 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Treatment of neovascular age-related macular degeneration within 48 h from diagnosis improves long-term functional outcome;Biomedicine & Pharmacotherapy;2023-04
2. Managing Neovascular Age-Related Macular Degeneration in Clinical Practice: Systematic Review, Meta-Analysis, and Meta-Regression;Journal of Clinical Medicine;2022-01-10
3. Management of neovascular age-related macular degeneration: Taiwan expert consensus;Journal of the Formosan Medical Association;2021-12
4. Predicting Incremental and Future Visual Change in Neovascular Age-Related Macular Degeneration Using Deep Learning;Ophthalmology Retina;2021-11
5. Real-World Outcomes of Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration: A Large-Scale Postmarketing Surveillance in Korea;Clinical Ophthalmology;2021-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3